Wegovy vs Mounjaro: Which Is Better for Weight Loss? A TrimRX Comparison

Choosing between Wegovy and Mounjaro is one of the most common questions we hear from patients starting their weight loss journey. Both medications have transformed the landscape of medical weight management, but they work differently, produce different levels of results, and may be better suited to different patients depending on their health history and goals. At TrimRX, our providers help patients navigate this decision with a clear understanding of how each medication performs based on the latest clinical evidence.

How Wegovy and Mounjaro Work Differently

While both Wegovy and Mounjaro belong to the injectable weight loss medication category, they use fundamentally different mechanisms to produce their effects.

Wegovy (semaglutide) is a GLP-1 receptor agonist. It works by mimicking a single gut hormone called GLP-1, which helps regulate appetite, slow stomach emptying, and improve blood sugar control. Wegovy is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It is also approved for adolescents aged 12 and older.

Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist. In addition to activating the same GLP-1 pathway as Wegovy, it also targets GIP receptors. This dual mechanism may provide additional benefits for fat metabolism and appetite regulation beyond what GLP-1 alone can achieve. Mounjaro is currently FDA-approved for type 2 diabetes management, though its weight-loss-specific formulation is marketed as Zepbound.

As clinical analysts have noted, this dual GIP and GLP-1 activity may result in greater weight reduction for some patients compared to single-pathway medications.

Weight Loss Results: What the Data Shows

When it comes to the numbers, the clinical evidence consistently shows that Mounjaro tends to produce greater average weight loss than Wegovy. However, the full picture is more nuanced than a simple percentage comparison.

Head-to-head analyses published in 2025 found that Mounjaro achieved approximately 20.2% average body weight loss compared to Wegovy’s 13.7% over comparable treatment periods. Data from the SURMOUNT-1 trial showed that patients on the highest Mounjaro dose (15 mg) lost an average of 22.5% of their body weight over 72 weeks, while Wegovy trial results typically range from 15% to 21% depending on the study and population.

To put this in practical terms: for a patient weighing 200 pounds, Mounjaro’s advantage could translate to roughly 44 pounds of total weight loss compared to approximately 30 pounds with Wegovy over a six-month period, according to comparative analyses.

However, it is important to note that no direct head-to-head clinical trial has been conducted comparing these two medications specifically for weight loss. The comparisons available come from reviews of separate diabetes trials and indirect data analysis. Individual results vary significantly, and many patients achieve excellent outcomes with either medication.

Beyond Weight Loss: Cardiovascular and Other Benefits

Weight loss percentages are not the only factor worth considering when choosing between these medications. Each one offers distinct advantages depending on your overall health profile.

Wegovy has a proven cardiovascular edge. Clinical trial data demonstrated a 20% reduction in major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular death, in overweight and obese patients with existing heart disease. This is a significant advantage for patients whose primary health concern extends beyond weight to cardiovascular risk management. Wegovy has also received FDA expansion for MASH (metabolic dysfunction-associated steatohepatitis), formerly known as fatty liver disease.

Mounjaro may offer superior weight and blood sugar outcomes. For patients whose primary goal is maximum weight reduction or who also need to manage blood glucose levels, Mounjaro’s dual-action mechanism has shown a consistent advantage in clinical data. The additional GIP receptor activation appears to boost fat metabolism in ways that GLP-1-only medications do not.

This is why at TrimRX, our providers take a personalized approach. A patient with cardiovascular risk factors may benefit more from Wegovy’s proven heart protection, while a patient focused purely on weight loss goals may see better results with Mounjaro.

Side Effects: Are They Different?

One of the most common misconceptions about these medications is that their side effect profiles are significantly different. In reality, both Wegovy and Mounjaro share a very similar gastrointestinal side effect profile. The most frequently reported symptoms for both include:

• Nausea (especially during dose titration)
• Diarrhea
• Constipation
• Decreased appetite
• Vomiting
• Abdominal discomfort

These side effects are typically most noticeable when starting the medication or increasing the dose, and they tend to improve over time as your body adjusts. Neither medication has demonstrated a major tolerability advantage over the other in clinical comparisons. Both follow a gradual titration schedule designed to minimize these effects.

Your TrimRX provider can help you manage side effects with practical strategies regardless of which medication you choose.

Cost and Access Considerations

Affordability and insurance coverage are practical factors that influence many patients’ decisions. The cost landscape for both medications continues to evolve:

• Mounjaro may offer better uninsured pricing, with savings programs bringing costs to as low as $25 per month for eligible patients. Without insurance or savings programs, the list price is substantial but may be lower out-of-pocket than Wegovy in some situations.
• Wegovy may offer better insured pricing for patients with compatible coverage, with some plans reducing costs to $0 copay. However, coverage varies widely by insurer and plan type.
• Telehealth programs like TrimRX can help simplify access by working with patients to identify the most cost-effective pathway based on their insurance status and financial situation.

Compounded alternatives have also emerged due to access and cost barriers, though patients should exercise caution and work with legitimate, regulated providers to ensure medication quality and safety.

Which One Should You Choose?

There is no single answer to which medication is universally better. The right choice depends on your individual health profile, goals, and circumstances. Here is a general framework our providers use when discussing options with patients:

• Consider Mounjaro/Zepbound if: Your primary goal is maximum weight loss, you need blood glucose management alongside weight loss, or you are looking for the strongest average weight reduction based on available clinical data.
• Consider Wegovy if: You have existing cardiovascular risk factors or heart disease history, you need a medication with explicit FDA approval for weight management, you are under 18 (Wegovy is approved for ages 12+), or cardiovascular protection is a priority alongside weight loss.

Both medications represent significant advances in medical weight management, and many patients achieve life-changing results with either option. The key is working with a knowledgeable provider who can evaluate your complete health picture.

Frequently Asked Questions

Is Mounjaro FDA-approved for weight loss?

Mounjaro is currently FDA-approved for type 2 diabetes management only. Its weight-loss-specific formulation is called Zepbound, which uses the same active ingredient (tirzepatide) and identical dosing. When prescribed for weight loss through telehealth, Mounjaro may be used off-label. Wegovy, by contrast, holds explicit FDA approval for chronic weight management.

Can I switch from Wegovy to Mounjaro or vice versa?

Switching between GLP-1 medications is possible under medical supervision. However, when switching to a new medication, patients typically need to restart at the lowest dose regardless of what dose they were on previously. Your TrimRX provider can guide you through a safe transition if a switch is appropriate for your situation.

Do Wegovy and Mounjaro have different side effects?

Both medications share essentially the same gastrointestinal side effect profile, including nausea, diarrhea, and constipation. Clinical comparisons have not identified a major tolerability gap between the two. Side effects tend to be most noticeable during dose titration and generally improve with time.

How much more weight can I expect to lose on Mounjaro compared to Wegovy?

Based on available clinical data, Mounjaro tends to produce approximately 6 percentage points more weight loss than Wegovy on average (roughly 20% vs 14% of body weight). However, individual results vary widely, and some patients respond better to one medication than the other. Your provider can help set realistic expectations based on your health profile.

Has there been a direct head-to-head trial comparing Wegovy and Mounjaro for weight loss?

No direct head-to-head clinical trial comparing these two medications specifically for weight loss has been completed. Current comparisons are drawn from separate trials, diabetes reviews, and indirect data analysis. This is an important distinction, as study populations and protocols differed across trials.

Get Personalized Guidance from TrimRX

Choosing the right weight loss medication is a medical decision that should be made with professional guidance based on your complete health history. At TrimRX, our licensed providers evaluate your individual needs, risk factors, and goals to recommend the best treatment option for you.

Start your treatment today. Talk to a TrimRX provider and find out which medication may be the right fit for your weight loss journey.